Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Abstract Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | https://doi.org/10.1186/s13045-023-01462-0 |